Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
Date:12/11/2008

NEW YORK, Dec. 11 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP") System for the treatment of cancers of the liver, announced today that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver. The eleven participating cancer centers in this trial continue to evaluate and enroll patients and the Company looks forward to completing enrollment in 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Commenting on this important event, Richard L. Taney, President and Chief Executive Officer of Delcath, stated, "Enrollment of the forty-sixth patient in this trial represents a significant milestone for our Company as we continue to accelerate this trial and accrue the data to support FDA approval of the Delcath PHP System. Attaining the midpoint of this trial, on the heels of expanding to eleven centers, is an important confirmation that the Company remains on the clinical and regulatory schedule discussed with investors over the past six months. The clinical data for the first 46 patients will be submitted to the Data Safety Monitoring Board for evaluation, once we complete the collection of follow-up data on the recently treated patients. We look forward to updating our investors during our upcoming conference call to be held next month."

This multi-center clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under this CRADA, patients for this study are being treated at the NCI and at ten cancer centers
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
4. Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial
5. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
8. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
9. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
11. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 The participants committed to not ... spending their own time adjusting, tweaking and testing virtual ... were ready for judging. , “I enjoyed being involved ... leader. “The entries showed a commendable range exploring ... of the print medium and the creativity of the ...
(Date:10/1/2014)... September 30, 2014 In response ... tools to address sales, training and consumer engagement ... developed innovative mobile applications to turn their clients’ ... agency’s latest customized mobile app creations, are now ... , In partnership with Toyota, StudioPMG created a ...
(Date:10/1/2014)... Award winning unified communications (UC) and ... collaboration bundles that combine next generation communication technologies. ... for low, flat rate fees. With four ... optimized solutions to meet their technology needs. , ... minutes (1K, 5K, 10K increments) or audio minutes ...
(Date:10/1/2014)... 2014 TeselaGen Biotechnology has ... to expand their bioCAD/CAM software suite, which uses ... The Small Business Innovation Research Phase II grant will ... exclusive license from the Lawrence Berkeley National Laboratory. j5 ... an LBNL laboratory that develops alternative fuel technologies for ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Calif., Oct. 8 KineMed Inc., a privately,held pathway-based ... Fineman, CEO and President of KineMed, will present an,overview ... the 4th Annual,BIO Investor Forum in San Francisco on ... Heights room of the Palace Hotel. Mr. Fineman will,provide ...
... 7 Protalix,BioTherapeutics, Inc. (Amex: PLX ), ... public offering of its common stock pursuant to ... The company is proposing to sell 3,726,708 shares ... proposing to sell an,aggregate of 1,242,236 shares of ...
... President, Research Operations - Dr. ... CARLSBAD, Calif., Oct. 5 Ardea Biosciences,Inc. ... the discovery and,development of small-molecule therapeutics for the ... announced changes to its,research management. Dr. Jean-Luc Girardet ...
Cached Biology Technology:KineMed to Present at the 4th Annual BIO Investor Forum 2Protalix BioTherapeutics Announces Public Offering of Common Stock 2Protalix BioTherapeutics Announces Public Offering of Common Stock 3Ardea Biosciences Announces Changes to Research Management 2Ardea Biosciences Announces Changes to Research Management 3
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
(Date:9/29/2014)... ramosum , coupled with a high-fat diet, may cause animals ... mBio , the online open-access journal of the American ... German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed that ... gained weight when fed a high-fat diet. Mice that did ... when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2
... previous work with engines traveling on straight tracks, a ... of Oxford have successfully used DNA building blocks to ... of tracks with multiple switches. The findings, published in ... Nature Nanotechnology , are expected to lead to further ...
... at the RIKEN SPring-8 Center in Harima, Japan have ... reductase (qNOR), a bacterial enzyme that offers clues on ... to their importance to fundamental science, the findings provide ... ozone-depleting and greenhouse gas hundreds of times more potent ...
... San Diego Zoo Institute for Conservation Research scientists shows ... condor in the wild are human influenced, with lead ... birds. , The study documents the deaths of ... Baja, California, Mexicofrom the inception of the reintroduction program ...
Cached Biology News:New study sheds light on evolutionary origin of oxygen-based cellular respiration 2Scientific paper shows California condor still threatened by human activities 2
... tissue extracts (liver, kidney, spleen, and heart) and ... It was also tested with microsomal fractions prepared ... simple and reliable method for measuring NDPase activity ... the inorganic phosphate released from NDP by the ...
... Principle: The sulfidoleukotrienes ... are products of arachidonic acid ... In the past, they were ... of Anaphylaxis (SRS-A)". They are ...
... the condition in which a lack of ... the various antioxidants. Oxidative stress appears ... several diseases, including artherosclerosis, chronic inflammatory diseases, ... antioxidant systems that are very important for ...
... Compound(s) tested through 63 ... assays spanning a broad ... panel includes many non ... several non-selective assays. ...
Biology Products: